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The optimal protocol for the histopathological examination of sentinel lymph nodes (SLNs) in breast cancer has not been
determined. The value of more detailed examination using immunohistochemistry (IHC) is controversial. A total of 476 SLNs from
216 patients were reviewed. Sentinel lymph nodes were sectioned at three levels at 100mm intervals and stained with haematoxylin
and eosin (H&E). If the H&E sections showed no evidence of metastasis, then the three serial sections were stained with a murine
monoclonal anti-cytokeratin antibody (CAM 5.2). Metastatic deposits were classified as macrometastasis (42.0mm),
micrometastasis (0.2–2.0mm) or isolated tumour cells (ITC, o0.2mm). Of the 216 patients, 56 (26%) had metastasis as identified
by H&E. Immunohistochemistry detected metastatic deposits in a further nine patients (4%), of whom four (2%) had micrometastasis
and five (2%) had ITC only. Those cases with micrometastases were all, on review, visible on the H&E sections.
Immunohistochemistry detects only a small proportion of metastasis in SLNs. All metastatic deposits identified by IHC were
either micrometastasis or ITC. Until the prognostic significance of these deposits has been determined, IHC may be of limited value in
the histopathological examination of SLNs.
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Breast carcinoma is the leading cause of death in women with over
300000 deaths annually worldwide (Pisani et al, 1999a,b). Axillary
lymph node (ALN) status is one of the most important prognostic
factors in breast cancer. Traditionally, ALN staging has been
achieved by histopathological examination of lymph nodes
retrieved during ALN dissection (ALND) or four-node sampling
of the axilla. Modern standard histopathological work-up in most
institutions consists of haematoxylin & eosin (H&E) staining of a
limited number of macroscopic slices of the lymph node, usually
between 1 and 4, depending on the size of the node. This may
underestimate the disease status in some patients. Recent studies
have shown that more exhaustive examination of the lymph nodes
by serial sectioning, immunohistochemistry (IHC) or molecular
techniques (e.g. by polymerase chain reaction, PCR) increases the
detection of ALN metastasis compared with routine H&E
methodology (van Diest et al, 1999; Cserni, 2004). The major
disadvantage of these techniques is that they are highly labour-
intensive and too time-consuming to be routinely applied to all
lymph nodes retrieved in an ALND. Secondly, the evidence that
axillary node status is of prognostic significance is based on
routine H&E methodology, often from historical series in which a
smaller proportion of the lymph node was examined than is
standard practice today.
More recently, sentinel lymph node biopsy (SLNB) has been
proposed as an alternative method for staging the axilla in women
who have early breast cancer with clinically node negative axillae
(Giuliano et al, 1994; Veronesi et al, 1997; McIntosh and
Purushotham, 1998; Veronesi et al, 1999; Veronesi et al, 2003).
The SLN is the first lymph node to receive lymphatic drainage
from a tumour. It is therefore the node most likely to contain
metastatic breast carcinoma. A tumour-free SLN virtually excludes
lymphatic involvement of the entire regional lymphatic basin
(Turner et al, 1997). Sentinel lymph node biopsy allows a more
detailed histological analysis to be performed within the context of
a routine histopathology laboratory, as more sections can be
scrutinised and additional techniques such as immunohistochem-
ical staining methods can be applied, if desired. However, there is
currently no internationally accepted standardised protocol for the
histological examination of SLNs. As a result, some institutions
have developed their own, in-house guidelines, and many use a
combination of serial sectioning and/or IHC.
We carried out a retrospective review of the histopathological
assessment of SLNs in our unit with the aim of determining the
value of IHC in the detection of metastatic deposits in SLNs when
compared to H&E examination alone.
PATIENTS AND METHODS
SLN biopsy
Between November 1999 and September 2004, 216 patients
underwent SLNB at Addenbrooke’s Hospital in Cambridge, UK.
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sWritten informed consent was obtained from all patients. Patients
considered eligible for SLN had unifocal tumours up to 40mm on
ultrasound, with a proven histopathological diagnosis of invasive
breast cancer on core biopsy. Pregnant patients, patients with
clinically involved axillary nodes or with multifocal breast cancer,
previous diagnostic excision biopsy and those who previously had
treatment for breast cancer (e.g. neoadjuvant chemotherapy) were
excluded from the study.
All patients underwent conventional wide local excision (WLE)
or mastectomy to remove the primary tumour. The SLN was
detected using a dual technique of radioisotope and patent blue
dye. Briefly, between 2 and 24h prior to the operation, a single
dose of up to 40MBq of 99mTc-nanocolloid (0.2ml; Gipharma
S.r.l., Italy) was injected into the breast. Routes for injection
included the subdermal, intradermal and intratumoral route.
Subdermal/intradermal injections were performed either around
the areola or into the skin overlying the tumour. After induction of
anaesthesia, a dose of 2.0ml patent blue dye (2.5% Bleu patente ´
V
s, Guerbet, France) with 3.0ml 0.9% saline was injected in the
periareolar region of the breast. The area was massaged for 5min
to optimise uptake of the dye by the lymphatics. The SLN was
identified by its bluish discolouration. If no blue node was
detected, a gamma probe was used to trace the SLN. The node(s) in
question were excised and the wound explored with the probe for
additional blue and/or ‘hot’ nodes that might represent further
SLNs. If the SLNs revealed histological evidence of metastatic
spread (i.e. macrometastasis or micrometastasis), the patient was
readmitted for an ALND. If only isolated tumour cells (ITC) were
detected in the SLNs, a further surgical procedure was carried out
only in exceptional circumstances.
Histopathology of the SLNs and ALNs
All SLNs measuring less than 5mm in maximum diameter were
bisected and both halves processed for histological examination.
Nodes, which were greater than 5mm in maximum diameter, were
sliced into at least three slices at approximately 2–3mm intervals
and all the slices were embedded, in as many cassettes as were
required. All slices of each node were routinely processed through
to paraffin wax. Blocks were sectioned at three levels at 100mm
intervals and stained with H&E. If the H&E sections showed no
evidence of metastasis on histological examination, then the three
serial sections from all blocks were stained with a murine
monoclonal anti-cytokeratin antibody (CAM 5.2, Becton-Dick-
inson Biosciences, UK).
The lymph nodes removed during conventional axillary
dissection were examined according to National Health Service
Breast Screening Programme (NHSBSP) pathology reporting
guidelines (NHS Cancer Screening Programmes & The Royal
College of Pathologists, 2005). Briefly, nodes greater than 5mm in
diameter were sliced at 2–3mm intervals and several slices
examined in a single cassette, those less than or equal to 5mm in
diameter were embedded unsliced. Sections from each lymph node
were stained with H&E. Immunohistochemistry was not performed
on lymph nodes obtained from standard ALND, except where
required by the histopathologist for investigation of suspicious
cells.
For histological reporting of SLNB and ALND specimens, UK
National Guidelines were used (NHS Cancer Screening Pro-
grammes and The Royal College of Pathologists, 2005). Specifi-
cally, all metastases greater than 2.0mm in size were classified as
macrometastasis. A micrometastasis was diagnosed when one or
more deposits of metastatic carcinoma were seen measuring more
than 0.2mm in size, but none of which was larger than 2.0mm.
Isolated tumour cells were reported when single or small clusters
of tumour cells were identified measuring not more than 0.2mm in
maximum dimension.
RESULTS
The histopathological characteristics of the primary tumours are
shown in Table 1. A total of 476 SLNs were available for analysis
(mean 2.2 per patient, range 1–7). Of the 216 patients analysed, 56
(26%) had SLN metastasis as identified by H&E only. A further
nine patients (4%) had metastatic deposits detected by IHC
(Table 2), of whom four (2% of total, 44% of those detected by
IHC) had micrometastatic disease (Figure 1), ranging from 0.2 to
1.0mm in size. The remaining five patients had ITC (3% of total
patients, 56% of those detected by IHC; Figure 2). One patient (A)
had a suspicious 0.2mm deposit identified on H&E, and an actin
immunohistochemical stain was performed to determine the
presence or absence of a myoepithelial layer. The micrometastases
were readily identified on the original H&E sections in all four
cases when the slides were reviewed (by SEP). In no case were ITC
detected when the original H&E slides were reviewed.
Seven of the IHC positive patients had an ALND. In all seven
patients, SLN was the only positive node in this series.
DISCUSSION
Sentinel lymph node biopsy is rapidly emerging as an alternative
to ALND in staging the axilla in patients with early breast cancer
and is routinely performed in many institutions around the world.
Although SLNB has recently been incorporated into the TNM
classification (Sobin et al, 2002), the optimal histopathological
workup of SLNs is currently not standardised. A recent survey of
practices in a large number of European institutions revealed wide
discrepancies internationally as well as nationally (Cserni et al,
2004a). Although some countries have set up national guidelines
for specimen handling, many institutions have developed their
own guidelines for SLN processing, which are more intensive than
the national guidelines recommend as a minimum, and which are
frequently determined by the institution’s research strategy.
The issue is further complicated by the rapid advances in
molecular techniques that allow identification of even the smallest
metastatic deposits down to single isolated tumour cells. Almost
all data relating to the prognostic significance of ALN involvement
in invasive breast cancer are based on examination of a single
standard H&E-stained section, often of one slice of each lymph
node. Invariably, the majority of the metastases detected by this
Table 1 Histopathological characteristics of the study population
Characteristic No (%)
n 216 (100)
Mean tumour size in mm (range 4–40mm) 15.1
0–9 35 (16)
10–19 131 (61)
20–29 37 (17)
30–40 13 (6)
Tumour type
Invasive ductal/NST 155 (72)
Invasive lobular 20 (9)
Special types 41 (19)
Histological grade
1 46 (21)
2 110 (51)
3 60 (28)
Receptor status
ER positive 189 (87)
ER negative 27 (13)
Lympho-vascular invasion
Absent 190 (88)
Present 26 (12)
NST¼no special type; ER¼oestrogen receptor.
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stechnique would have been what would now be classified as
macrometastasis.
Two issues need to be taken into consideration when designing
a protocol for SLN examination. Firstly, what is the minimum size
of metastatic deposit that one should aim to identify (i.e.
macrometastasis, micrometastasis or ITC)? Secondly, what is the
optimal protocol for detecting a metastatic deposit of a given size?
There are as yet no definitive answers to these issues, although
some evidence is available that may offer some guidance as to how
to address these issues.
It is self evident that a more detailed examination of lymph
nodes increases the percentage of metastases found (Sapir and
Amromin, 1948; Pickren, 1961). Recent reports have estimated that
step-sectioning with H&E staining and IHC results in the
‘upstaging’ of about 10 and 20% of patients, respectively (van
Diest et al, 1999; Cserni, 2004). The majority of these tumour
deposits are likely to be micrometastasis or ITC.
The prognostic significance of SLN micrometastasis, whether
detected by H&E serial sectioning, IHC or a combination of both is
controversial (Dowlatshahi et al, 1997; Tjan-Heijnen et al, 2001;
Noguchi, 2002). The contradictory reports in the literature
probably reflect the heterogeneity of this population of tumours
in terms of their metastatic potential. The on-going American
College of Surgeons Oncology Group (ACOSOG) Z0011 trial will
help to determine the significance of SLN micrometastasis detected
by IHC (protocol available at ACOSOG) (www.acosog.org).
Until further evidence regarding the prognostic significance of
SLN micrometastasis is available, it would seem reasonable to
propose that the identification of macrometastases should be the
minimum standard in SLN histopathology. A number of recent
reports have applied mathematical models of SLN metastasis in an
Table 2 Characteristics of SLN (micro)metastases missed on initial H&E examination
Tumour characteristics
Patient ID Size of metastasis (mm) Seen on review of H&E Size (mm) G T LVI ER Non-SLN metastasis
A 0.2 Yes 11 1 ST No +ve No
B 0.6 Yes 20 2 ST No +ve No
C 1.0 Yes 21 3 NST Yes  ve No
D 0.9 Yes 23 2 NST No +ve No
E ITC No 25 2 ILC No +ve No
F ITC No 20 2 NST No +ve No
G ITC No 13 2 NST No +ve No
H ITC No 10 2 NST Yes +ve N/A
a
I ITC No 32 2 NST No +ve N/A
a
ITC¼isolated tumour cells; H&E¼haematoxylin and eosin; G¼grade; T¼tumour type; LVI¼lympho-vascular invasion; ER¼oestrogen receptor; SLN¼sentinel lymph node;
ILC¼invasive lobular carcinoma; NST¼invasive carcinoma of ductal/no special type; ST¼invasive carcinoma of special type.
aALND (axillary lymph node dissection) not done.
Figure 1 A micrometastatic deposit present only in the levels of this
SLN shown by IHC (A) and on H&E (B).
Figure 2 ITCS present in the periphery of this SLN were only identified
with IHC and were not even on review, visible on H&E.
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allows a metastasis of a defined size to be identified (Meyer, 1998;
Farshid et al, 2000; Cserni, 2004). Cserni (2004) demonstrated that
a step-sectioning protocol of levels separated by 250mm will
detect all macrometastases of a size of 2.0mm or greater. However,
if a higher threshold for the detection of macrometastases is
chosen, the workload can be reduced considerably. For example,
by examining levels separated by 1.0mm, all macrometastases
measuring 2.2mm or more will be detected, resulting in a
reduction of the workload by 75%. Since metastases of this size
are usually seen on H&E stains, IHC will only be required in rare
cases where the epithelial nature of suspicious cells needs to be
confirmed.
If the aim of the histopathological examination of the SLN is to
identify micrometastases as well, then the extent of the protocol
has to be increased considerably. On the basis of the geometrical
model described by Cserni (2004), sections separated by 200mm
would detect all micrometastases and not misclassify them as
ITC. These sectioning protocols require that the entire node is
sectioned, resulting in a considerable workload for the pathology
department.
Farshid et al (2000) developed a mathematical model of an
average SLN from histological survey data. In a series of
simulations, the virtual SLN generated by the model was subjected
to various sectioning protocols currently in use that were evaluated
for their ability to detect micrometastatic deposits of specified
sizes. In addition, the authors performed a cost analysis for the
different protocols. Slicing the node into fine slices as opposed to
bisecting it increased the chances of detecting micrometastasis in
the range of 50mm to 2.0mm. The increase was two-fold for 2mm
slices and four-fold for 1mm slices. The increased detection rate
could be achieved at a small increase in cost. However, the costs
for this approach rose significantly when applied to larger lymph
nodes, as in these cases the tissue usually had to be embedded in
several blocks. Consistent with other reports, the inclusion of serial
sections increased the likelihood of detecting micrometastasis.
Again, only the most detailed protocol consisting of serial sections
of fine slices of the entire node was able to detect all
micrometastasis of X200mm. In all, only two of the six protocols
evaluated had detection rates of 30% or higher for micrometastasis
of X500mm. Interestingly, cost was not a good discriminator for
efficiency. Two of the better performing strategies were more
expensive, but two other protocols with similar costs had poor
detection rates. The value of using IHC on SLN sections was not
addressed by the model.
It has been demonstrated that the majority of metastases will be
detected in the first few sections examined (Cserni, 2002; Yared
et al, 2002). Yared et al (2002) examined 10 levels of serially
sectioned SLNs and performed IHC on levels 3 and 8, while the
remaining levels were stained with H&E. The authors found that
the first two H&E or the first cytokeratin-stained levels were
positive for metastases in 96%. Two additional H&E-stained and
one cytokeratin-stained level of each SLN correctly identified the
status of the node in 98% of cases. It seems, therefore, that limiting
the number of sections to the initial few, at intervals that will
reliably identify macrometastases, might represent a reasonable
compromise between sensitivity and workload.
An alternative strategy to limit the extent of the analysis would
be to examine those areas of the SLN first that are most likely to
contain metastatic deposits. Two recent studies have suggested
that metastatic deposits have a higher probability of being located
in the region of the inflow junction of the afferent lymphatic vessel
(Cserni, 2000; Diaz et al, 2003). Theoretically, and speculatively,
this region could potentially be marked by the surgeon intra-
operatively when the blue-stained lymphatic is followed to the
SLN, and sections with a higher probability of containing
metastases could then be targeted at the initial histopathological
examination. Further, more detailed evaluation would be carried
out only if the initial sections were negative. In practice, however,
this may be impossible and further evidence will be required to
determine the value of this strategy.
If, as the evidence from the literature suggests, serial sectioning
increases the detection rate of SLN metastasis, what is the place of
IHC? Immunohistochemistry facilitates detection of small meta-
static deposits by direct labelling of the tumour cells. Review of
slides stained by IHC would require less time by the pathologist,
which in turn would allow a greater number of sections to be
screened. On the other hand, increasing the number of immuno-
histochemically prepared sections will increase costs and put
considerable strain on laboratory resources. As SLN biopsy
becomes the standard of care in many institutions, IHC requests
would lead to an exponential increase in costs and few laboratories
will have the facilities or resources to meet the demand. As an
extreme example, Weaver (2003) has calculated the costs for
performing IHC on 10mm sections on an average of two SLNs per
patient in the US. Leaving aside interpretive costs, this would
amount to $4800 per case, or more than $690 million annually, and
approximately 57 million slides would have to be screened per
year. Apart from costing and resources issues, human error and
false positive results need to be taken into account. Rescreening of
IHC slides by an automated image analysis system revealed missed
metastatic deposits in up to 10% of patients (Weaver et al, 2003).
Furthermore, considerable interobserver variability in reading
IHC-stained sections of SLN has been reported (Roberts et al,
2003). False positive results can occur with some of the most
commonly employed low molecular weight cytokeratin antibodies
(Domagala et al, 1992; Xu et al, 2000; Rao et al, 2005). To avoid
false positivity caused by fibroblastic-type reticular cells and other
cells, assessment needs to be based on immunoreactivity and
morphological criteria. Thus, an H&E-stained section is also
required. Potentially, if H&E and IHC are used in combination, the
H&E slides may not be scrutinised as meticulously because the
pathologist may rely on the subsequent IHC stain to pick up any
missed metastases. This may have been the case in the present
series, as the micrometastases identified by IHC were visible on
H&E when the sections were reviewed. Careful examination of
H&E sections at levels of 250mm is sufficient to identify the large
majority of SLN macrometastases. A proportion of micrometas-
tases will also be identified by this protocol but inevitably some
will be missed. The main advantage of IHC lies in facilitating the
identification of some additional very small (o2.0mm) deposits
and ITCs, although many micrometastases will be detected by
careful scrutiny of the H&E sections alone. Current UK Pathology
guidelines do not recommend the routine use of IHC on SLN
outside clinical trials and aim to identify the macrometastatic
disease (NHS Cancer Screening Programmes & The Royal College
of Pathologists, 2005). We hope, with our strategy of undertaking
additional levels, to identify some (but not all) micrometastatic
disease, as described above. In our hands, IHC was of little
additional value to the initial H&E stains. Over half of the deposits
detected by IHC (five out of nine) were ITC alone and were not
established metastatic deposits. Since the prognostic value of ITC
is unknown and further therapeutic decisions are not based on the
presence of ITC as a rule, omitting IHC would not have altered
management in these patients. The remaining four IHC-positive
cases, 2% of the entire study population, consisted of micro-
metastases, all of which were readily identified on the original H&E
stains when the slides were reviewed. None of the micrometastases
identified on IHC had further metastases in the non-SLN. Others
have found non-SLN metastasis in approximately 9% of SLNs
positive on IHC only (Cserni et al, 2004b). This difference may be
due to the small number of cases observed in our study or due to
differences in histological protocols.
As a result of this study, we have changed our practice and have
abandoned IHC on SLN, unless suspicious cells on the initial H&E
stain require further investigation. This has reduced our costs and
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sturnaround time. This study did not address the value of step
sectioning, but evidence from the literature suggests that if
additional tests are to be performed on the SLN, this might be
the most cost effective.
Results from the clinical trials looking at the prognostic
significance of micrometastasis will help to determine whether
techniques for detection of these smaller deposits should be
included in routine SLN specimen handling protocols.
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